Abstract:Background: There are few data comparing clinical outcomes of complex percutaneous coronary intervention (CPCI) when using biodegradable polymer drug-eluting stents (BP-DES) or second-generation durable polymer drug-eluting stents (DP-DES). The purpose of this study was to investigate the safety and efficacy of BP-DES and compare that with DP-DES in patients with and without CPCI during a 5-year follow-up. Methods: Patients who exclusively underwent BP-DES or DP-DES implantation in 2013 at Fuwai Hospital were consecutively enrolled and stratified into two categories based on CPCI presence or absence. CPCI included at least one of the following features: unprotected left main lesion, ≥2 lesions treated, ≥2 stents implanted, total stent length >40 mm, moderate-to-severe calcified lesion, chronic total occlusion, or bifurcated target lesion. The primary endpoint was major adverse cardiac events (MACE) including all-cause death, recurrent myocardial infarction, and total coronary revascularization (target lesion revascularization, target vessel revascularization [TVR], and non-TVR) during the 5-year follow-up. The secondary endpoint was total coronary revascularization. Results: Among the 7712 patients included, 4882 (63.3%) underwent CPCI. Compared with non-CPCI patients, CPCI patients had higher 2- and 5-year incidences of MACE and total coronary revascularization. Following multivariable adjustment including stent type, CPCI was an independent predictor of MACE (adjusted hazard ratio [aHR]: 1.151; 95% confidence interval [CI]: 1.017–1.303, P = 0.026) and total coronary revascularization (aHR: 1.199; 95% CI: 1.037–1.388, P = 0.014) at 5 years. The results were consistent at the 2-year endpoints. In patients with CPCI, BP-DES use was associated with significantly higher MACE rates at 5 years (aHR: 1.256; 95% CI: 1.078–1.462, P = 0.003) and total coronary revascularization (aHR: 1.257; 95% CI: 1.052–1.502, P = 0.012) compared with that of DP-DES, but there was a similar risk at 2 years. However, BP-DES had comparable safety and efficacy profiles including MACE and total coronary revascularization compared with DP-DES in patients with non-CPCI at 2 and 5 years. Conclusions: Patients underwent CPCI remained at a higher risk of mid- to long-term adverse events regardless of the stent type. The effect of BP-DES compared with DP-DES on outcomes was similar in CPCI and non-CPCI patients at 2 years but had inconsistent effects at the 5-year clinical endpoints.

Drug-eluting stents in clinical routine: a 1-year follow-up analysis based on German health insurance administrative data from 2008 to 2014

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

ASSA13-15-7 Drug-Eluting Stenting Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: A Meta-Analysis Based on Time-To-Event Data from Randomised Controlled Trials

Risk factors for clinical events at 1-year follow-up after drug-eluting stent implantation: results from the prospective multicenter German DES.DE registry

Comparative outcomes of drug-coated balloon angioplasty versus second-generation drug-eluting stent for in-stent restenosis: a real-world data analysis

Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?

Comparison of Drug-Eluting Stents with Bare Metal Stents Implantation for the Treatment of Acute ST-elevation Myocardial Infarction: 2-Year Clinical Outcomes from Single-Center Registry.

Ten‐year clinical outcomes after drug‐eluting stents implantation according to clinical presentation—Insights from the DECADE cooperation

Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)

Comparison of the efficacy of drug-eluting stents versus bare-metal stents for the treatment of left main coronary artery disease.

Mid-term result of implantation of drug eluted stent for diabetic patients with multivessel coronary artery lesions

Five-year outcomes of biodegradable versus second-generation durable polymer drug-eluting stents used in complex percutaneous coronary intervention

Long‐term outcomes of DCB and DES for the treatment of in‐stent restenosis in relation to the vessel size

Different drugs in drug-eluting stents for peripheral artery disease: a systematic evaluation and Bayesian meta-analysis

Peripheral Artery Disease Intervention: Drug-Coated Balloon vs Drug-Eluting Stent, A Long-Term Comparison

Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study

Percutaneous coronary intervention of in-stent restenosis: A three-arm analysis from SWEDEHEART

Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study

Long-term Outcomes Following Drug-Eluting Stent Implantation in Unprotected Left Main Bifurcation Lesions.